Abstract
Metformin is one of the oldest oral hypoglycaemic (PAD) used in the treatment of 2 diabetes mellitus type (DM2). It belongs to a group of insulin sensitizers, ie substances that directly affect the secretion of insulin, but improve the sensitivity of peripheral tissues to the action of insulin, or present reduces insulin resistance (IR). primary target tissue blood sugar lowering effect of metformin the liver.
